Exopharm Ltd
ASX:EX1
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Exopharm Ltd
ASX:EX1
|
AU |
|
IDI SCA
PAR:IDIP
|
FR |
|
E
|
Endo International PLC
LSE:0Y5F
|
IE |
|
K
|
Karmarts PCL
SET:KAMART
|
TH |
|
D
|
DMS Co Ltd
KOSDAQ:068790
|
KR |
|
Beyond Air Inc
NASDAQ:XAIR
|
US |
|
I
|
InternetArray Inc
OTC:INAR
|
US |
|
China Bester Group Telecom Co Ltd
SSE:603220
|
CN |
|
SSP Group PLC
LSE:SSPG
|
UK |
|
S
|
Spinnaker Acquisitions PLC
LSE:SPAQ
|
UK |
Exopharm Ltd
Exopharm Ltd. engages in the development and commercialization of exosomes as therapeutic agents. The company is headquartered in Melbourne, Victoria. The company went IPO on 2018-12-18. The firm is focused on developing and commercializing exosomes as therapeutic agents. The firm has three technologies that allows customization of exosomes, in which the LOAD technology improves loading of nucleic medicines into exosomes and the EVPS technology allows exosomes to be directed towards selected cell types. Its LEAP manufacturing technology provides access to exosomes for research and clinical uses. The firm is developing Engineered EVs (EEVs), are an emerging form of precision medicine with application in areas, such as neurology, cardiology and oncology. Its EEV projects under development are Fortrexo, Cognevo and PlexoDOX.
Exopharm Ltd. engages in the development and commercialization of exosomes as therapeutic agents. The company is headquartered in Melbourne, Victoria. The company went IPO on 2018-12-18. The firm is focused on developing and commercializing exosomes as therapeutic agents. The firm has three technologies that allows customization of exosomes, in which the LOAD technology improves loading of nucleic medicines into exosomes and the EVPS technology allows exosomes to be directed towards selected cell types. Its LEAP manufacturing technology provides access to exosomes for research and clinical uses. The firm is developing Engineered EVs (EEVs), are an emerging form of precision medicine with application in areas, such as neurology, cardiology and oncology. Its EEV projects under development are Fortrexo, Cognevo and PlexoDOX.
